Harukaze Yamamoto

1.0k total citations
25 papers, 794 citations indexed

About

Harukaze Yamamoto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Harukaze Yamamoto has authored 25 papers receiving a total of 794 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Harukaze Yamamoto's work include Cancer Treatment and Pharmacology (6 papers), PARP inhibition in cancer therapy (5 papers) and HER2/EGFR in Cancer Research (4 papers). Harukaze Yamamoto is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), PARP inhibition in cancer therapy (5 papers) and HER2/EGFR in Cancer Research (4 papers). Harukaze Yamamoto collaborates with scholars based in Japan, United States and United Kingdom. Harukaze Yamamoto's co-authors include Kenji Tamura, Yasuhiro Fujiwara, Kan Yonemori, Chikako Shimizu, Takayuki Kinoshita, Mayu Yunokawa, Hitoshi Tsuda, Masashi Ando, Noriyuki Katsumata and Makoto Kodaira and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Journal of Cancer.

In The Last Decade

Harukaze Yamamoto

24 papers receiving 782 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harukaze Yamamoto Japan 12 548 285 182 133 127 25 794
Sébastien Gouard France 18 259 0.5× 450 1.6× 178 1.0× 87 0.7× 159 1.3× 37 758
Géraldine Gebhart Belgium 14 614 1.1× 610 2.1× 229 1.3× 53 0.4× 169 1.3× 26 980
Andrea Milani Italy 12 416 0.8× 81 0.3× 208 1.1× 109 0.8× 268 2.1× 35 765
Yunjiang Liu China 13 517 0.9× 154 0.5× 235 1.3× 53 0.4× 186 1.5× 57 813
Devika Gajria United States 12 536 1.0× 190 0.7× 136 0.7× 44 0.3× 322 2.5× 31 867
Kazutoshi Murata Japan 15 259 0.5× 125 0.4× 264 1.5× 175 1.3× 127 1.0× 53 751
Zohreh Varasteh Sweden 21 610 1.1× 727 2.6× 225 1.2× 88 0.7× 310 2.4× 42 1.2k
Eleonora Nicolò Italy 12 496 0.9× 222 0.8× 179 1.0× 52 0.4× 116 0.9× 39 635
Vadim S. Koshkin United States 18 544 1.0× 143 0.5× 483 2.7× 92 0.7× 335 2.6× 118 1.3k
Simon Peter Gampenrieder Austria 15 654 1.2× 234 0.8× 245 1.3× 49 0.4× 247 1.9× 56 937

Countries citing papers authored by Harukaze Yamamoto

Since Specialization
Citations

This map shows the geographic impact of Harukaze Yamamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harukaze Yamamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harukaze Yamamoto more than expected).

Fields of papers citing papers by Harukaze Yamamoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harukaze Yamamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harukaze Yamamoto. The network helps show where Harukaze Yamamoto may publish in the future.

Co-authorship network of co-authors of Harukaze Yamamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Harukaze Yamamoto. A scholar is included among the top collaborators of Harukaze Yamamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harukaze Yamamoto. Harukaze Yamamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shimomura, Akihiko, Kan Yonemori, Masayuki Yoshida, et al.. (2019). Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. Translational Oncology. 12(10). 1386–1394. 7 indexed citations
2.
Yonemori, Kan, Akihiko Shimomura, Hiroyuki Yasojima, et al.. (2019). A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. European Journal of Cancer. 109. 84–91. 25 indexed citations
3.
Tanabe, Yuko, Chikako Shimizu, Akinobu Hamada, et al.. (2017). Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer Chemotherapy and Pharmacology. 79(6). 1179–1186. 40 indexed citations
4.
Kurihara, Hiroaki, Chikako Shimizu, Yasuji Miyakita, et al.. (2015). Molecular imaging using PET for breast cancer. Breast Cancer. 23(1). 24–32. 24 indexed citations
5.
6.
Kurihara, Hiroaki, Akinobu Hamada, Masayuki Yoshida, et al.. (2015). 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Research. 5(1). 86 indexed citations
7.
Hirakawa, Akihiro, Kan Yonemori, Yachiyo Kuwatsuka, et al.. (2014). A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan. Current Drug Safety. 9(3). 220–226. 1 indexed citations
8.
Tamura, Kenji, Hiroaki Kurihara, Kan Yonemori, et al.. (2013). 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer. Journal of Nuclear Medicine. 54(11). 1869–1875. 228 indexed citations
9.
Yunokawa, Mayu, Noriyuki Katsumata, Harukaze Yamamoto, et al.. (2013). A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer. Cancer Chemotherapy and Pharmacology. 71(5). 1369–1374. 7 indexed citations
10.
Tanabe, Yuko, Chikako Shimizu, Akihiro Hirakawa, et al.. (2013). Potential use of Pain Vision as an objective method to evaluate chemotherapy-induced peripheral neuropathy.. Journal of Clinical Oncology. 31(15_suppl). e20557–e20557. 1 indexed citations
11.
Ito, Yukiko, Takeshi Sawada, Masaru Watanabe, et al.. (2013). Abstract 1446: Detection of circulating tumor cells for malignant epitherial tumor using a novel cytometry-based system.. Cancer Research. 73(8_Supplement). 1446–1446. 2 indexed citations
12.
Yamamoto, Harukaze & Kenji Tamura. (2012). Chemotherapy: Phase Two progress and future perspectives. 61. 564–568. 1 indexed citations
13.
Kojima, Yuki, Kenji Hashimoto, Masashi Ando, et al.. (2012). Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis. Cancer Chemotherapy and Pharmacology. 70(3). 391–397. 15 indexed citations
14.
Ono, Makiko, Hitoshi Tsuda, Chikako Shimizu, et al.. (2011). Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Research and Treatment. 132(3). 793–805. 245 indexed citations
15.
Ono, Makiko, Masashi Ando, Kan Yonemori, et al.. (2011). Second-line chemotherapy in patients with primary unknown cancer. Journal of Cancer Research and Clinical Oncology. 137(8). 1185–1191.
16.
Hashimoto, Kenji, Kan Yonemori, Noriyuki Katsumata, et al.. (2011). Use of squamous cell carcinoma antigen as a biomarker of chemotherapy response in patients with metastatic cervical carcinoma. European Journal of Obstetrics & Gynecology and Reproductive Biology. 159(2). 394–398. 12 indexed citations
17.
Ando, Masashi, Kan Yonemori, Noriyuki Katsumata, et al.. (2011). Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 69(2). 457–465. 32 indexed citations
18.
Hashimoto, Kenji, Kan Yonemori, Chikako Shimizu, et al.. (2010). A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer. Medical Oncology. 28(2). 434–440. 3 indexed citations
19.
Yonemori, Kan, Tsutomu Kouno, Masashi Ando, et al.. (2010). Influence of Suboptimal Treatment in Patients with Mediastinal Primary Nonseminomatous Germ Cell Tumors. Oncology. 78(1). 34–39. 1 indexed citations
20.
Yamamoto, Harukaze, Ikuo Sekine, Kazuhiko Yamada, et al.. (2008). Gender Differences in Treatment Outcomes among Patients with Non-Small Cell Lung Cancer Given a Combination of Carboplatin and Paclitaxel. Oncology. 75(3-4). 169–174. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sébastien Gouard Breakdown of academic impact, for papers by Géraldine Gebhart Breakdown of academic impact, for papers by Andrea Milani Breakdown of academic impact, for papers by Yunjiang Liu Breakdown of academic impact, for papers by Devika Gajria Breakdown of academic impact, for papers by Kazutoshi Murata Breakdown of academic impact, for papers by Zohreh Varasteh Breakdown of academic impact, for papers by Eleonora Nicolò Breakdown of academic impact, for papers by Vadim S. Koshkin Breakdown of academic impact, for papers by Simon Peter Gampenrieder
Rankless by CCL
2026